Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorIcahn School of Medicine at Mount Sinai
About this trial
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
Eligibility criteria
Qualifiers
Patients ≥ 18 years
Newly diagnosed lymphoma
Scheduled to receive high-dose anthracycline (cumulative dose ≥ 300 mg/m2)
Eastern Cooperative Oncology Group (ECOG) performance status 0-3
Disqualifiers
Prior anthracycline treatment
Previous malignancy requiring any chemotherapy or radiotherapy
Previous treatment with SGLT2i (eg due to T2DM) or SGLT1/2i
Previous heart failure (HF patients should already be on SGLT2i as per guidelines)
Trial design
Treatments tested in this trial
- Sotagliflozin
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Icahn School of Medicine at Mount Sinai
Lead sponsor
American Heart Association
Collaborator
Source ClinicalTrials.gov